Hepatic regenerative medicine: exploiting the liver's will to live.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. New insights on the role of vascular endothelial growth factor in biliary pathophysiology.JHEP reports : innovation in hepatology · 2021
   Review
2. The effects of astaxanthin on liver histopathology and expression of superoxide dismutase in rat aflatoxicosis.The Journal of veterinary medical science · 2019
   Article
3. GC-1: A Thyromimetic With Multiple Therapeutic Applications in Liver Disease.Gene expression · 2017
   Review
4. Thyroid Hormone Receptor-β Agonist GC-1 Inhibits Met-β-Catenin-Driven Hepatocellular Cancer.The American journal of pathology · 2017
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

Indexed as